This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

PreTarg-it®: A Mechanism-Guided Pretargeting Strategy to Maximize Tumor Targeting, Improve Therapeutic Windows, and Overcome Resistance Mechanisms

PreTarg-it®: A Mechanism-Guided Pretargeting Strategy to Maximize Tumor Targeting, Improve Therapeutic Windows, and Overcome Resistance Mechanisms

2:00 pm - Thursday 23rd July 2026

Bringing together the strengths of two worlds: antibody-driven tumor specificity and accumulation with the rapid systemic clearance of small molecules for selective tumor irradiation.
Targeting tumor-specific antigens oxMIF and HER2 with pharmacokinetically optimized antibodies to ensure persistent tumor irradiation while sparing healthy tissue
Offering a mechanism-guided strategy to maximize therapeutic efficacy and addressing tumor resistance mechanisms

Speakers:

Alexander Schinagl

Co-Founder & Chief Technology Officer

OncoOne